Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)

Durvalumab 1500 mg every 4 weeks x 3 cycles

Tremelimumab 75 mg every 4 weeks x 3 cycles

"Regimen 1: 21-day treatment cycle x 3 cycles.~* Gemcitabine 1,000-1,200 mg/m2 intravenously on days 1 and 8 every 21 days.~* Cisplatin 70 mg/m2 intravenously on day 1 every 21 days. Regimen 2: ddMVAC 14-day treatment cycle x 4 doses.~* Methotrexate 30mg/m2 intravenously on day 1~* Vinblastine 3mg/m2 intravenously on day 2~* Doxorubicin 30mg/m2 intravenously on day 2~* Cisplatin 70mg/m2 intravenously on day 2 Granulocyte colony-stimulating factor (G-CSF) for 7 consecutive days (days 4 through 10).~Regimen 3: 21-day treatment cycle x 3 cycle~* Gemcitabine 1,000 mg/m2 intravenously on day 1 and 8~* Paclitaxel 80 mg/m2 intravenously on day 1 and 8~* Cisplatin 70mg/m2 intravenously on day 1"